Solid Biosciences (SLDB) Return on Capital Employed (2018 - 2026)

Solid Biosciences has disclosed Return on Capital Employed across 9 years of filings, most recently posting 66.05% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 66.05%, down 588.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 66.05% (down 588.0% YoY), and the FY2025 annual result was 101.17%, down 1265.0% from the prior year.
• Return on Capital Employed came in at 66.05% for Q1 2026 at Solid Biosciences, up from 81.55% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 40.73% in Q1 2022 to a low of 81.55% in Q4 2025.
• The 5-year median for Return on Capital Employed is 56.46% (2024), against an average of 57.93%.
• Across the five-year window, Return on Capital Employed slumped 1998 bps in 2022 and soared 1249 bps in 2024, its largest moves.
• Solid Biosciences' Return on Capital Employed stood at 53.26% in 2022, then slipped by 22 bps to 65.03% in 2023, then fell by 17 bps to 76.32% in 2024, then retreated by 7 bps to 81.55% in 2025, then rose by 19 bps to 66.05% in 2026.
• The last three Return on Capital Employed figures came in at 66.05% (Q1 2026), 81.55% (Q4 2025), and 66.61% (Q3 2025), per Business Quant data.